RecruitingNCT06440148
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Role of Sclerostin in Mastocytosis Bone Disease
Sponsor
Medical University of Lublin
Enrollment
50 participants
Start Date
Sep 1, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues. Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Age \> 18 years
- Mastocytosis defined according to WHO criteria
- Known KIT mutation status
Exclusion Criteria4
- History of organ transplant
- Inability to give informed consent
- Pregnancy, Breastfeeding
- Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALSCLEROSTIN
Pathogenesis of mastocytosis bone disease
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06440148
Related Trials
Study of Factors Regulating Mast Cell Proliferation
NCT000441221 location
Institutional Registry of Rare Diseases
NCT065737231 location
Analysis of the Role of IgE Proteoforms in Health and Disease
NCT073281781 location
Myeloproliferative Neoplasms (MPNs) Patient Registry
NCT027602381 location
Mastocytosis Registry (of Zurich)
NCT064668891 location